Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34

ConclusionsTogether, these findings from in vitro, ex vivo, and in vivo models show that SMIP34 may be a useful therapeutic agent for inhibiting PELP1 signaling in TNBC.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research